Tetrasodium {5-[(4-chloro-6-{[4-(alkenylsulfonyl)phenyl]amino}-heteromonocycl-2-yl)amino]-4-(hydroxy-κO)-3-{[2-(hydroxy-κO)phenyl]diazenyl-κN}naphthalene-disulfonato(4-)}[3-(hydroxy-κO)-4-{[2-(hydroxy-κO)naphthalen-1-yl]diazenyl-κN}naphthalene-sulfonato(3-)]chromate(4-)

Basic toxicokinetics

Administrative data

Endpoint:

basic toxicokinetics

Type of information:

other: Expert assessment

Adequacy of study:

key study

Study period:

The study was conducted on 19 June 2015

Data source

Reference

Reference Type:

other: Expert assessment

Title:

Unnamed

Year:

2015

Report date:

2015

Materials and methods

Principles of method if other than guideline:

In accordance with Annex VIII of Regulation (EC) No. 1907/2006 (REACH) a paper based toxicokinetic assessment has been conducted for this substance.

Results and discussion

Any other information on results incl. tables

In accordance with Annex VIII of Regulation (EC) No. 1907/2006 (REACH) a paper based toxicokinetic assessment has been conducted for this substance. Summaries were reviewed by a qualified toxicologist. The assessment of the likely toxicokinetic behaviour of the substance was provided to the extent that can be derived from the relevant available information at the time of the assessment. The available information suggests that the substance is readily available via the oral route. This is supported by the physic-chemical properties of the substance. Once absorbed, the substance would be distributed systematically in the serum. Urinary excretion is considered to be the significant elimination route for the substance.